Union Chimique Belge

What Union Chimique Belge does

UCB SA/NV (Union Chimique Belge) is a Brussels-headquartered global biopharmaceutical company founded in 1928 and listed on Euronext Brussels (ticker UCB; U.S. OTC ADR UCBJY), focused on developing and commercializing specialty medicines for severe neurological, immunological, and rare diseases. Its commercial portfolio is anchored by five growth-driver franchises — BIMZELX (bimekizumab, the first IL-17A/F dual inhibitor approved across five indications in 50+ countries, with FY2025 net sales above €2.2 billion), FINTEPLA (fenfluramine, for Dravet, Lennox-Gastaut, and CDKL5 deficiency disorders), ZILBRYSQ (zilucoplan, a once-daily subcutaneous C5 inhibitor with a pre-filled pen in Europe), RYSTIGGO (rozanolixizumab, an FcRn antibody fragment for myasthenia gravis), and KYGEVVI (the first and only FDA- and EMA-approved treatment for thymidine kinase 2 deficiency). Established legacy products include CIMZIA, KEPPRA, VIMPAT, BRIVIACT, and EVENITY (co-developed with Amgen).

The underlying technology platform centers on antibody discovery and biologics engineering at the Braine-l'Alleud (Belgium) and Windlesham (UK) R&D campuses, with additional capabilities in cell and gene therapy, AI/ML-enabled bioprocess optimization through the DNAlytics Hercule platform, and a new ~$2B digital-first U.S. biologics manufacturing facility in Gwinnett County, Georgia. UCB supplements organic discovery with a heavy licensing and M&A engine, exemplified by recent acquisitions of Neurona Therapeutics ($1.15B for NRTX-1001 cell therapy), Candid Therapeutics ($2.2B for cizutamig BCMAxCD3 bispecific TCE), IMIDomics (AI-enhanced immunology biobank), and the worldwide Antengene license for ATG-201.

UCB generates revenue primarily through branded pharmaceutical product sales distributed via country-specific commercial subsidiaries in 40+ countries, specialty pharmacies, and hospital channels, complemented by licensing royalties (e.g., ATG-201 up to $1.1B+ in milestones plus tiered royalties) and co-development collaborations (e.g., Biogen for dapirolizumab pegol in SLE). Pricing follows country-specific reimbursement frameworks rather than public disclosure; UCBCares provides multilingual patient and HCP support across 30+ countries. FY2025 total revenue reached €7.74 billion (+26% YoY) with adjusted EBITDA of €2.64 billion (+79%), and 2026 guidance calls for high single-digit to low double-digit revenue growth at constant exchange rates.

Name

Union Chimique Belge

Legal name

UCB SA/NV (Union Chimique Belge)

Website

https://ucb.com

Company type

Public

Founded year

1928

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

UCB is a Belgian global biopharmaceutical company developing and commercializing specialty medicines for severe neurological, immunological, and rare diseases, with growth anchored by five product franchises across 40+ countries.

Ownership category

akta.pro rank

Headquarters

HQ city

Brussels

HQ country

Belgium

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations, Supply Chain

Revenue model

1. Branded Pharmaceutical Product Sales: Primary revenue from sales of proprietary branded biopharmaceutical products (BIMZELX, FINTEPLA, KEPPRA, VIMPAT, CIMZIA, ZILBRYSQ, RYSTIGGO, KYGEVVI, EVENITY) across neurology, immunology, and rare disease therapeutic areas. FY 2025 net sales reached €7.39 billion, up 32% YoY.
2. Licensing & Royalty Income: Revenue from licensing agreements including global exclusive license of ATG-201 from Antengene ($80M upfront + over $1.1B milestones + tiered royalties) and Staccato alprazolam licensing milestones (up to $60.5M plus tiered royalties).
3. Co-Development & Collaboration Revenue: Revenue from collaboration agreements including the Biogen/UCB partnership for dapirolizumab pegol in systemic lupus erythematosus, and oncology alliance with Cancer Research UK and Cancer Research Horizons.
4. Out-licensed AI-Powered Antibody Discovery: Revenue from AI-driven antibody design partnerships, including licensing with Ailux Biologics, supporting next-generation biologics development.

Pricing tiers

Go-to-market motion4 records

Distribution channels6 records

Marketing channels8 records

Core offering

UCB is a global biopharmaceutical company that researches, develops, manufactures, and commercializes innovative specialty medicines for severe neurological, immunological, and rare diseases. The company sells proprietary branded pharmaceuticals (BIMZELX, FINTEPLA, KYGEVVI, ZILBRYSQ, RYSTIGGO, CIMZIA, KEPPRA, VIMPAT, BRIVIACT, EVENITY) and operates the UCBCares patient support service across 40+ countries.

Product overview

UCB operates as a global biopharmaceutical company with a portfolio-plus-pipeline architecture rather than a single unified software product. Its core revenue-generating platform consists of five growth-driver pharmaceutical franchises (BIMZELX/bimekizumab, RYSTIGGO, FINTEPLA/fenfluramine, ZILBRYSQ/zilucoplan, and KYGEVVI/doxecitine and doxribtimine) that together delivered more than €3.3 billion in combined 2025 net sales, on top of established products including CIMZIA, EVENITY, BRIVIACT, and VIMPAT. UCB's pipeline is being expanded aggressively through acquisitions (Candid Therapeutics' cizutamig for $2.2 billion, Neurona Therapeutics' NRTX-1001 for $1.15 billion, IMIDomics' AI-enhanced biobank platform) and licensing deals (Antengene's ATG-201 for autoimmune diseases, Alexza/Lee's Pharm's Staccato alprazolam). Underpinning the commercial organization is UCBCares, the company's patient and HCP support service, and Veeva Safety Suite for global pharmacovigilance, while digital transformation is enabled by AI, robotics, and automation across the new $5 billion U.S. biologics manufacturing facility in Georgia and the DNAlytics Hercule bioprocess platform.

Differentiator

Problem solved

Functional benefit

Brands

• BIMZELX (bimekizumab): Flagship IL-17A/F inhibitor for psoriasis, psoriatic arthritis, axial spondyloarthritis and hidradenitis suppurativa; net sales exceeded €2.2 billion in 2025.
• KYGEVVI (doxecitine and doxribtimine)
• FINTEPLA (fenfluramine)
• ZILBRYSQ (zilucoplan)
• CIMZIA (certolizumab pegol)
• KEPPRA (levetiracetam)
• VIMPAT (lacosamide)
• BRIVIACT (brivaracetam)
• EVENITY (romosozumab)
• RYSTIGGO (rozanolixizumab)
• Dapirolizumab Pegol (DZP)

Products and services

• BIMZELX (bimekizumab)
• FINTEPLA (fenfluramine) Antiseizure medication for seizures associated with Dravet syndrome and Lennox-Gastaut syndrome, also being developed for CDKL5 Deficiency Disorder. Acquired via Zogenix in 2022.
• KYGEVVI (doxecitine and doxribtimine) First and only FDA- and EMA-approved treatment for thymidine kinase 2 deficiency (TK2d), an ultra-rare genetic mitochondrial disease. Approved by FDA November 2025 and by EU March 2026.
• ZILBRYSQ (zilucoplan) Once-daily subcutaneous complement component 5 (C5) inhibitor for adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis. First once-daily subcutaneous C5 inhibitor available as a pre-filled pen in Europe.
• RYSTIGGO (rozanolixizumab)
• VIMPAT (lacosamide)
• CIMZIA (certolizumab pegol)
• EVENITY (romosozumab)
• BRIVIACT (brivaracetam)
• KEPPRA (levetiracetam)
• Dapirolizumab Pegol (DZP) Investigational anti-CD40L pegylated Fab being co-developed with Biogen for systemic lupus erythematosus. Phase 3 PHOENYCS GO 48-week results showed sustained disease control.
• Cizutamig (acquired via Candid Therapeutics)
• NRTX-1001 (acquired via Neurona Therapeutics)
• ATG-201 (licensed from Antengene) CD19/CD3 bispecific T-cell engager antibody licensed worldwide to UCB from Antengene targeting B cell-related autoimmune diseases; IND approved by China's NMPA in 2026.
• UCBCares
• Staccato alprazolam

Quantifiable outcome

• FY2025 revenue grew 26% YoY to €7.74 billion with adjusted EBITDA up 79% to €2.64 billion
• +9 more outcomes

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration9 records

AI capability18 records

Feature10 records

Partnerships

19 partnerships are on record, tiered minor - licensing deal for early-stage multiple sclerosis candidate, core - immunology data and biobank platform acquisition, core - scientific capability expansion partnerships, major - unified global pharmacovigilance platform partner, core - implementation partners for pharmacovigilance transformation, core - oncology innovation network partner, major - ongoing late-stage collaboration in lupus and immunology, minor - terminated merger after ucb's candid deal, minor - advisory role for ai adoption in biopharma, core - strategic oncology alliance for novel cancer therapies, flagship - $2.2b acquisition for next-generation immunology pipeline, minor - founding investors of acquired entity, flagship - $1.15b acquisition for regenerative cell therapy expansion into epilepsy, core - renewable energy supply chain decarbonization, major - $1.1b+ global licensing deal for cd19/cd3 bispecific tce, core - multi-pharma federated ai/ml consortium for biologics, core - cns pipeline asset licensing agreement, minor - research collaboration for sleep eeg biomarkers and flagship - $1.9b acquisition establishing ucb's epilepsy franchise.

• Pheno Therapeuticsminor - licensing deal for early-stage multiple sclerosis candidateOEM/ Whitelabel/ Licensing Partner · 22 June 2026UCB holds exclusive worldwide license to Pheno Therapeutics' PTD802, a selective GPR17 antagonist for remyelination in multiple sclerosis. PTD802 received FDA IND clearance (and prior UK MHRA CTA approval), making it the first GPR17 program to receive IND clearance globally, enabling first-in-human clinical trials.
• IMIDomicscore - immunology data and biobank platform acquisitionStrategic or Co-development Partner · 19 June 2026UCB acquired IMIDomics to leverage its comprehensive data and biobank platform enhanced by AI and machine learning for immunology research and development. Combined with Neurona and Candid acquisitions, this is part of UCB's strategic acquisition series in neuroscience and immunology innovation.
• Candid Therapeutics and Antengenecore - scientific capability expansion partnershipsStrategic or Co-development Partner · 19 June 2026Partnerships with Candid Therapeutics and Antengene expand UCB's scientific capabilities in T and B cell modulation to restore immunological tolerance, complementing its organic immunology pipeline.
• Veeva Systemsmajor - unified global pharmacovigilance platform partnerTechnology or Integration · 12 June 2026UCB selected Veeva Safety Suite to unify its global pharmacovigilance operations, enabling faster case processing, enhanced oversight, and streamlined regulatory submissions on a single cloud platform. The June 1, 2026 go-live, delivered in collaboration with ELIQUENT Life Sciences, Pinnaxis, and Daelight Solutions, migrated 14 million documents and 80 million records - one of the first complete suite implementations globally.
• ELIQUENT Life Sciences, Pinnaxis, and Daelight Solutionscore - implementation partners for pharmacovigilance transformationImplementation/ SI/ Consulting Partner · 12 June 2026ELIQUENT Life Sciences (regulatory affairs partner) delivered the Veeva Safety Suite deployment for UCB in collaboration with Pinnaxis and Daelight Solutions. Daelight Solutions migrated 14 million documents and 80 million records into the single cloud-based platform combining case processing, signal management, and reporting.
• Cancer Research Horizonscore - oncology innovation network partnerStrategic or Co-development Partner · 12 June 2026Jointly with Cancer Research UK, Cancer Research Horizons contributes its oncology innovation network and translational research expertise to accelerate development of novel cancer therapies targeting high unmet medical need.
• Biogen Inc.major - ongoing late-stage collaboration in lupus and immunologyStrategic or Co-development Partner · 4 June 2026UCB and Biogen co-developed dapirolizumab pegol (DZP) for systemic lupus erythematosus (SLE). Phase 3 PHOENYCS GO study results presented at EULAR 2026 showed 48-week sustained disease control with glucocorticoid tapering to ≤7.5 mg/day. Both companies discussing regulatory path forward. Multiple earlier-stage pipeline assets in lupus, MS, and Parkinson's also discussed.
• Rallybiominor - terminated merger after ucb's candid dealOthers · 21 May 2026Rallybio's planned $505M reverse merger with Candid Therapeutics was derailed by UCB's $2.2B acquisition of Candid. Rallybio subsequently received a $50M termination fee from Candid and pivoted to a reverse merger with Avenzo Therapeutics, raising $215M from Blackstone and OrbiMed.
• DrugBankminor - advisory role for ai adoption in biopharmaOthers · 12 May 2026Dr. Mike Branson (SVP at UCB) serves as an inaugural member of DrugBank's Advisory Board to guide AI adoption in biopharma. The board addresses AI credibility in scientific and medical workflows amid record AI investment but lagging data infrastructure in biopharma.
• Cancer Research UK and Cancer Research Horizonscore - strategic oncology alliance for novel cancer therapiesStrategic or Co-development Partner · 7 May 2026UCB, Cancer Research UK, and Cancer Research Horizons formed a strategic alliance to accelerate development of novel cancer therapies. The collaboration combines UCB's antibody discovery and biologics capabilities with Cancer Research UK's translational research infrastructure and Cancer Research Horizons' oncology innovation network, focusing on targeted therapies for high unmet need.
• Candid Therapeuticsflagship - $2.2b acquisition for next-generation immunology pipelineStrategic or Co-development Partner · 3 May 2026UCB acquired Candid Therapeutics for up to $2.2B ($2B upfront + $200M milestones) to gain cizutamig, a BCMAxCD3 bispecific T-cell engager antibody being evaluated in 10+ autoimmune indications across over 100 patients. Candid was formed through merger of TRC 2004 and Vignette Bio, with Two River and Vida Ventures as founding investors. Deal expected to close by end of Q2/early Q3 2026.
• Two River and Vida Ventures (Bellco Health ecosystem)minor - founding investors of acquired entityOthers · 22 April 2026Two River (founder of TRC 2004) and Vida Ventures (founder of Vignette Bio) played central roles in founding Candid Therapeutics through the merger of TRC 2004 and Vignette Bio. Two River sourced one of Candid's lead assets from China. They successfully realized value through UCB's $2.2B acquisition of Candid.
• Neurona Therapeuticsflagship - $1.15b acquisition for regenerative cell therapy expansion into epilepsyStrategic or Co-development Partner · 17 April 2026UCB acquired Neurona Therapeutics for up to $1.15B ($650M upfront + $500M milestones) to gain NRTX-1001, an allogeneic neuronal cell therapy for drug-resistant mesial temporal lobe epilepsy currently in Phase I/II trials with FDA Regenerative Medicine Advanced Therapy and EMA PRIME designations. The deal marks UCB's strategic expansion into regenerative medicine, expected to close by end of Q2 2026.
• Zelestra (via Schneider Electric Energize Program)core - renewable energy supply chain decarbonizationOthers · 23 March 2026UCB participates as a multi-buyer in the Energize program for renewable electricity procurement, supporting three new solar plants in Cuenca, Spain (162 MW capacity, 42,700+ tonnes CO2 reduction annually) managed by Schneider Electric. UCB is one of the program's 25 sponsor pharmaceutical companies advancing healthcare supply chain decarbonization.
• Antengene Corporationmajor - $1.1b+ global licensing deal for cd19/cd3 bispecific tceOEM/ Whitelabel/ Licensing Partner · 3 March 2026UCB obtained worldwide exclusive license to develop, manufacture, and commercialize ATG-201, a CD19/CD3 bispecific T-cell engager for B cell-related autoimmune diseases. Antengene receives $80M upfront + $1.1B+ in development/regulatory/sales milestones plus tiered royalties. Antengene conducts first-in-human Phase I trials in China and Australia before transferring further clinical development to UCB.
• FAITE Consortium (AbbVie, Amgen, AstraZeneca, Johnson & Johnson)core - multi-pharma federated ai/ml consortium for biologicsStrategic or Co-development Partner · 28 December 2025UCB participates in the FAITE Consortium alongside AbbVie, Amgen, AstraZeneca, and Johnson & Johnson to collectively train AI models for biologics prediction using federated computing. This enables privacy-preserving cross-organizational collaboration compliant with HIPAA and GDPR, accelerating pharmaceutical R&D timelines.
• Lee's Pharmaceutical Holdings / Nova Pneuma Inc.core - cns pipeline asset licensing agreementOEM/ Whitelabel/ Licensing Partner · 11 December 2025Lee's Pharmaceutical acquired the Staccato® One Breath Technology® platform and Alexza's rights/obligations under the global licensing agreement with UCB. UCB's Staccato alprazolam (Phase 3 clinical trials) receives up to US$60.5M in milestone payments plus tiered royalties on global net sales. Two Phase 2 CNS assets (Parkinson's, Cyclic Vomiting Syndrome) added to pipeline.
• Beacon Biosignalsminor - research collaboration for sleep eeg biomarkersStrategic or Co-development Partner · 19 December 2024UCB collaborated with Beacon Biosignals on two posters at the American Epilepsy Society Annual Meeting showcasing sleep disturbance research in Lennox-Gastaut Syndrome using Beacon's FDA-cleared Dreem 3S EEG headband. The HEADFIRST study revealed LGS participants had reduced REM sleep (56.77 min vs. 104.34 min in neurotypical controls).
• Zogenix Inc.flagship - $1.9b acquisition establishing ucb's epilepsy franchiseStrategic or Co-development Partner · 19 January 2022UCB acquired Zogenix for up to $1.9B / €1.7B including contingent payments based on European regulatory approval for FINTEPLA in Lennox-Gastaut syndrome. The acquisition gave UCB FINTEPLA (fenfluramine), an epilepsy treatment for Dravet and Lennox-Gastaut syndromes, expanding UCB's rare disease neurology portfolio.

Scale indicators17 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• argenx: Belgium-based commercial-stage immunology biotech developing FcRn inhibitor VYVGART (efgartigimod) — directly comparable to UCB's RYSTIGGO in myasthenia gravis and across the broader IgG-mediated autoimmune space. Both are European-headquartered, antibody-focused, neurology/immunology specialists with comparable growth profiles.
• H. Lundbeck: Danish specialty pharma focused on CNS/neurology including epilepsy, migraine, and neurodegenerative diseases. Highly comparable therapeutic-area overlap with UCB's neurology franchise (epilepsy with VIMPAT/KEPPRA, FINTEPLA in DEEs) and similar mid-cap European specialty biopharma positioning.
• Ipsen: European specialty biopharma with strong neurology and rare disease portfolios. Comparable business model (specialty pharma sales-led motion, European HQ, focused therapeutic areas), overlapping customer base (neurologists, HCPs), and similar revenue scale.
• Recordati: Italian specialty pharma with European specialty commercial infrastructure and rare disease franchises. Closely comparable in business model (specialty biopharma, European-domiciled, HCP-focused GTM), therapeutic mix (rare disease, neurology-adjacent), and growth profile via organic plus bolt-on M&A.
• Jazz Pharmaceuticals: Mid-cap specialty pharma with strong neurology/epilepsy franchise (epidiolex, Xywav) and rare disease focus. Direct overlap with UCB's DEE/epilepsy portfolio and similar acquisition-led growth strategy in neurology and rare disease.
• Almirall: Spanish dermatology-focused specialty biopharma. Directly comparable on the immunology/dermatology side, particularly competing in psoriasis and hidradenitis suppurativa where UCB's BIMZELX is approved. Similar European specialty pharma operating model.
• Biogen: U.S.-headquartered neurology specialist and UCB's co-development partner for dapirolizumab pegol in SLE. Highly comparable in neurology focus (MS, SMA, lupus), pipeline stage, and antibody development capabilities; Biogen is the most direct partner-competitor in UCB's core therapeutic area.

Broad incumbents

• AbbVie: Global biopharma incumbent with HUMIRA/SKYRIZI immunology franchise that directly competes with BIMZELX in psoriasis/PsA, and FAITE consortium partner. Significantly larger and more diversified but a key benchmark for immunology competitive dynamics and partnership models relevant to UCB.
• Sanofi: Global biopharma with major immunology franchise (DUPIXENT) competing in the same immunology indications as BIMZELX, plus rare disease/neurology adjacencies. Larger and broader, but its specialty biopharma operating model and immunology commercial scale make it a relevant comparable for UCB.
• Amgen: Global biotech incumbent with EVENITY co-development partnership with UCB and broader immunology/oncology pipeline. FAITE consortium partner alongside UCB. Larger and more diversified but directly relevant as a competitive benchmark in biologics manufacturing and antibody development.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/ucb_news
• YouTubeyoutube.com/UCB
• Facebookfacebook.com/ucbbiopharma
• LinkedInlinkedin.com/company/ucb-pharma
• Instagraminstagram.com/ucbglobal

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles29 records

Subsidiaries19 records

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A13 records

Investments11 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Union Chimique Belge